

Higher mortality in men from COVID19 infection-understanding the factors that drive the differences between the biological sexes.

Swaminathan P. Iyer¹, Joe Ensor², Kartik Anand³, Patrick Hwu⁴, Vivek Subbiah⁴, Christopher Flowers¹, and Rudragouda Channappanavar⁵.

¹Department of Lymphoma and Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.

²Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston, Texas, USA

³Department of Oncology, Great Plains Health/Callahan Cancer Center, North Platte, Nebraska.

⁴Department of Medicine, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.

⁵Departments of Acute and Tertiary Care, and Microbiology, Immunology, & Biochemistry, Institute for the Study of Host-Pathogen Systems, The University of Tennessee Health Science Center

Corresponding author:

Swaminathan P. Iyer, MD

Department of Lymphoma and Myeloma

The University of Texas, MD Anderson Cancer Center

1400, Unit 429, Holcombe Blvd, Houston, TX

Phone: +1 713-792-5242

Fax:713-745-7423

Email: spiyer@mdanderson.org

Running Title: Biological Sex differences in COVID19

Keywords: COVID19, SARS-CoV, X-linked, TLR7

Word count: 1972

Abstract:

The emergent global pandemic caused by the rapid spread of Severe Acute Respiratory syndrome- Coronavirus-2 (SARS-CoV-2) has led to increased mortality and negatively impacted day to day activities of humankind within a short period of time. As the data is rapidly emerging from earlier outbreak locations around the world, there are efforts to assimilate this with the knowledge from prior epidemics and find rapid solutions for this. One of the observations and a recurring theme is the disproportionate differences in the incidence of infection and the consequent mortality between males and females. We, therefore, analyzed retrospective datasets from the previous epidemics and the ongoing pandemic in order to address these differences in clinical outcomes. The data shows that even though the infection rates are similar, the odds ratio of male mortality remains high, indicating a divergence in the crosstalk between the three pathogenic human Coronavirus (hCoVs)- the SARS-CoV, MERS-CoV and the SARS-CoV-2 and immune effectors in the two sexes. One proximate cause is the sex-specific modulation of the X-linked genes that can influence susceptibility to infection. Future studies are needed to confirm these findings, which can form the basis for developing rational strategies for ending the current and preventing future pandemics.

Introduction:

The World Health Organization (WHO) has recently declared SARS-CoV-2 initiated **Coronavirus disease 2019** (COVID19) as a pandemic^{1,2}. SARS-CoV-2 belongs to the coronaviruses (hCoVs) family that also include strains such as SARS-CoV, MERS-CoV, OC43, 229E, NL63, and HKU1³. The latter four are generally associated with self-limiting respiratory tract infections. However, unlike the seasonal strains, the SARS-CoV, MERS-CoV, and SARS-CoV2 strains cause outbreaks of severe respiratory disease in humans⁴⁻¹⁰. While SARS- and MERS-CoV spread among humans was limited, the current strain of SARS-coV-2 is rapidly being transmitted from human to human by aerosol or by direct contact leading to severe symptoms with accompanying pneumonia and acute respiratory distress in many patients. There are many similarities between COVID 19 and previous two similar outbreaks of human CoVs (hCoVs)- SARS that occurred in 2003 and the Middle Eastern Respiratory Syndrome (MERS) in 2012, in terms of the epidemiology, immunology and the extreme clinical manifestations. The two epidemiologic parameters include the basic reproduction number (R0) and the best estimates of case-fatality rates (CFR)*¹¹. The global epidemic of the 2002-2003 SARS outbreak caused over 8000 infections, including 774 deaths in 29 countries and an estimated CFR of 9.6% globally, while the MERS outbreak was estimated to have a much higher CFR of 34.5% with more than 2500 infections to date¹². Although several studies have shown an estimated R0 of 2.2 for COVID19, there is a broad range of values for the CFR given the inability to estimate during the early phase of this outbreak reliably. The risk for mortality shows an increase in the elderly population¹³ and in those with certain pre-existing conditions related to decreased or marginal

cardiac, pulmonary, renal functions, and immunosuppressive states. Another area that is gaining attention is the biological sex differences in the incidence of infection and CFR*.

Methods:

Studies chosen for these analyses were based on the availability of the sample size, and that of detailed patient demographics, including gender-associated incidence and mortality in peer-reviewed journals. The COVID19 sample set included the first three largest retrospective reports from China as they describe the unfolding clinical events and hospitals were trying to grapple with this sudden outbreak of the virus. Chen et al. describe a retrospective study from Wuhan Jinyintan hospital in the first three weeks of January. By that time, testing was available, and Guan et al. describe another retrospective case series at the First Affiliated Hospital of Guangzhou Medical University. Wang et al. describe the clinical outcomes of 138 patients with SARS-CoV-2 infected pneumonia at the Zhongnan Hospital of Wuhan University in Wuhan, China, between January 1 to January 28, 2020, with the final date of follow-up on February 3, 2020. For the SARS-CoV in 2003, the two studies include those compiled by Booth et al. in Toronto and another larger series by Karlberg et al. from China, Hong Kong, Special Administrative Region (Hong Kong SAR). The data set from the latter was derived from the published WHO report in 2003. Finally, the dataset for MERS-CoV includes the two largest series by Chen et al. and Alghamdi et al. that have detailed comparative epidemiology covering Saudi Arabia and South Korea. In order to accommodate statistical heterogeneity between these retrospective studies, we utilized the random effects model that assumes that different studies have different true exposure effects¹⁴. For individual studies, incidence and death rates are presented as percentages with 95% Wilson score confidence intervals. The percentage of

male cases was compared to 50% using a one-sample binomial test for proportions. Within the study, death rates were compared between males and females using a chi-square test. Results were aggregated across studies, and gender differences were compared using the GLIMMIX procedure of SAS to fit random effects model due to heterogeneity present in the datasets. All analyses were conducted using SAS 9.4, and statistical significance was defined as $p < 0.05^{15}$.

Results:

Biological sex differences between males and females in Incidence and mortality:

Sex-specific differences in disease incidence and severity were seen during the previous pathogenic hCoV outbreaks⁷⁻¹⁰. The incidence of COVID-19 and MERS seems to be more common among males, but SARS appears to be more common among females (Table 1 and Table 3a). The SARS epidemic in 2003 showed differences in incidence and mortality between males and females. Out of a total of 8098 SARS infections from 27 different countries- slightly more than half were female (World Health Organization, 2003). However, females had lower mortality rates from SARS than males, a pattern that is maintained after adjusting for age¹⁶. In the data reported from Hong Kong SAR, the mortality rate for males was 21.9%, which was substantially higher than the mortality rate for females of 13.2%¹⁰. The table 1 below is based on three studies from China^{4,5}. If one investigates whether the probability of being male is equivalent to being female (i.e., 50%), one would conclude that males were more likely to have the infection. Further review of CFR from SARS, MERS, and the ongoing COVID indicate a preferential outcome according to biological sex (Table 2 and Table 3b). In terms of mortality, males had increased deaths compared to females from MERS, SARS-CoV, and SARS-CoV2. (Table 2). The odds ratio of male mortality was 1.51 95%CI (1.08-2.08) in a study by Chen et al.

looking at cases from Saudi Arabia and South Korea⁷. The odds ratio of male mortality was higher at 2.2 95% CI (1.37-3.51) in the study of cases just from Saudi Arabia alone (Table 2). The odds ratio of male mortality was also higher, at 1.85-95% CI (1.43-2.3) from SARS-CoV^{9,10}. For the ongoing COVID19, the mortality data being collected is not entirely categorized by biological sex for some countries represented in Global Health 5050 COVID-19 data tracker¹⁷(Table 3b). Assuming a random effects model, the Global Health data yields an aggregate odds ratio (OR) of 1.84 for comparing the odds of death for males to females. There is statistically significant evidence in these studies strongly hinting at possible sex differences in the immune response.

Discussion:

There are reported differences in the rate of infection and mortality rates between men and women. Disaggregated data collections are necessary to understand the underlying biological and socio-economic (including behavioral) factors causing this. We have shown empiric data that the mortality rate for males is higher and statistically significant compared to females from the three hCoV outbreaks of MERS, SARS-CoV, and SARS-CoV2⁴⁻¹⁰. The data across show that there were 8-16 additional men with the disease for every 100 women infected. Guan et al. study showed higher male numbers, with 58% of 1099 reported. In the US, among 1,482 COVID19 patients reported from COVID-19–Associated Hospitalization Surveillance Network (COVID-NET), 74.5% were aged ≥ 50 years, and 54.4% were male¹⁸. It is also clear that men made a significant proportion of certain risk high-risk groups such as the elderly population and in those with certain pre-existing conditions related to decreased or marginal cardiac, pulmonary, renal functions, and immunosuppressive states continue to remain vulnerable. Data

from the China CDC indicate that the large numbers of deaths were elderly Chinese men with CFR of 14.8% in people 80 or older as opposed to 1.3% in 50-year old cohort and <0.5% in the younger population. The likely attributes here include a significant number of preexisting illnesses in men related to smoking and cardiovascular disease. In the COVID-NET dataset, the hospitalization rate was highest (13.8) among adults aged ≥ 65 years. Among 178 adult patients, 89.3% had one or more underlying conditions, including hypertension (49.7%), obesity (48.3%), chronic lung disease (34.6%), diabetes mellitus (28.3%), and cardiovascular disease (27.8%).

There is also a possibility that the apparent sex imbalance could reflect more exposure to the males because of frequent travel and contacts, as was reported in the MERS Saudi Arabian cohort. Since the virus appears to be transmitted primarily through large droplets and remains in aerosols for up to 3 days¹⁹, another factor that needs discussion is the gender differences in handwashing, particularly in public restrooms and airports. In a 2003 study of 175 individuals (95 women and 80 men) handwashing after restrooms use, indicated that women washed their hands with soap more often than men (61% vs. 37%) in the absence of a prompt to do so²⁰. When a visual reminder was placed, the numbers went up for women but remained more or less the same for men (97% vs. 35%). Indeed emphasis on handwashing with soap and the extent of time is one of the most effective interventions to prevent the spread across all age-groups and gender²¹.

Other possibilities include fundamental biological factors that may provide better immune protection for women, which may be related to the estrogen and X-linked genes and X chromosome inactivation (XCI)²². XCI or Lyonization is the process through which one X chromosome is inactivated to balance the dosage of gene expression between XX females and

XY males- this makes haploid males more susceptible to effects of the genetic variants. The X chromosome contains many genes that regulate the innate and adaptive immune system. These sex-based immunological differences have been shown to cause variations in susceptibility to infectious diseases and responses to vaccines and in the incidence of autoimmune diseases between males and females²²⁻²⁴. Some of these include pattern recognition receptors (PRRs) such as toll-like receptor (TLR)- TLR7 and TLR8, as well as Interleukin-1 receptor-associated kinase 1 (IRAK1), a key regulatory molecule in the TLR signaling pathway^{23,24}. Preclinical animal studies have also validated this sexual dimorphism in the severity of pneumonia caused by various respiratory pathogens with the highest correlation for the innate immune response triggered at the early phase of infection²⁵. Interestingly, Angiotensin converting enzyme 2 (ACE2), the receptor for both the SARS-CoV and the SARS-CoV-2 is encoded by its gene on Xp22. It has been shown that infection of human airway epithelia by hCoVs correlates with the state of bronchial epithelial cell differentiation and ACE2 expression and localization²⁶. There is evidence of adipose tissue ACE2 being regulated by estrogens, contributing to sex differences in the development of obesity-related hypertension in rat models²⁷. However, it is not clear if ACE2 genes are modulated differentially for SARS-CoV2 infection, although in a pre-print version on BioRxiv, Zhao et.al, show higher single-cell RNA expression profiling of ACE2 in two male donors compared to other 6 female donors²⁸. Finally, another candidate gene is the X-linked glucose-6-phosphate dehydrogenase (G6PD); the deficiency of the protein due to mutations is the most common enzymopathy, manifesting as hemolysis due to oxidative stress. Given the high prevalence of this mutation in African-Americans (1 in 10), Mediterranean and Asians, and the predilection for increased hCoV

infections in preclinical G6PD knockdown models, it is essential to elucidate its role in the outcomes to COVID infection^{29,30}. In summary, the evidence currently available for X chromosome studies involving X-linked innate immune genes remain incomplete and needs additional investigations to see if they are driving the differences.

Conclusions:

The odds ratio of male mortality still remains high in the largest outbreak in a century caused by the pathogenic hCoV- SARS-CoV-2. Our data is not adjusted for the various factors that could drive these differences, nevertheless, there are growing concerns about how the virus could disproportionately impact the different genders^{23,31}. Even though there is epidemiological data from pandemics, research and clinical practice do not reflect these distinctions. Ongoing research approaches should actively explore this area so that the knowledge derived can overcome this and prevent future pandemics. In addition we must collect disaggregated gender-relevant data that defines the various dimensions of this global epidemic. Moreover, aging studies in both sexes indicate diminished innate immune responses, and further analysis utilizing co-morbidities may provide the predilection for clinical worsening seen with this infection^{13,32}. Taken together, registry data capturing socio-economic and co-morbidity characteristics and clinical protocols targeting the various components of the innate immune system should be explored to address the sex-specific differences in COVID infection.

Author Contributions:

Conception and design: SPI, JE, and RC

Manuscript writing: SPI, JE, and RC

Final approval of manuscript: SPI, JE, KA, PH, MD, AH, VS, CF, and RC

Accountable for all aspects of the work: SPI, JE, KA, PH, MD, AH, VS, CF, and RC

Conflict of Interest: None to report

Legend:

Table 1: All Patients by Biological sex- incidence

Table 2: Death Rate by biological sex for SARS and MERS

Table 3: COVID19 All Patients by Biological sex- incidence

Table 4: COVID19 Death Rate by Biological sex

*Calculating the case-fatality ratio for a disease outbreak is difficult while the outbreak is still evolving. The true ratio cannot be determined until the outbreak is over when the total numbers of deaths and recoveries are known.

Reference:

1. Fauci AS, Morens DM. The perpetual challenge of infectious diseases. *N Engl J Med*. 2012;366(5):454-461.
2. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. *Acta Biomed*. 2020;91(1):157-160.
3. Gralinski LE, Baric RS. Molecular pathology of emerging coronavirus infections. *J Pathol*. 2015;235(2):185-195.
4. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395(10223):507-513.
5. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. *Eur Respir J*. 2020.
6. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *Jama*. 2020.
7. Chen X, Chughtai AA, Dyda A, MacIntyre CR. Comparative epidemiology of Middle East respiratory syndrome coronavirus (MERS-CoV) in Saudi Arabia and South Korea. *Emerg Microbes Infect*. 2017;6(6):e51.
8. Alghamdi IG, Hussain, II, Almalki SS, Alghamdi MS, Alghamdi MM, El-Sheemy MA. The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive epidemiological analysis of data from the Saudi Ministry of Health. *Int J Gen Med*. 2014;7:417-423.
9. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. *Jama*. 2003;289(21):2801-2809.
10. Karlberg J, Chong DS, Lai WY. Do men have a higher case fatality rate of severe acute respiratory syndrome than women do? *Am J Epidemiol*. 2004;159(3):229-231.
11. Viceconte G, Petrosillo N. COVID-19 R0: Magic number or conundrum? *Infect Dis Rep*. 2020;12(1):8516.
12. Riley S, Fraser C, Donnelly CA, et al. Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions. *Science*. 2003;300(5627):1961-1966.
13. Kennedy RB, Ovsyannikova IG, Haralambieva IH, et al. Immunosenescence-Related Transcriptomic and Immunologic Changes in Older Individuals Following Influenza Vaccination. *Front Immunol*. 2016;7:450.
14. Gardiner JC, Luo Z, Roman LA. Fixed effects, random effects and GEE: what are the differences? *Stat Med*. 2009;28(2):221-239.
15. SAS Institute C, NC. SAS Release 9.4. 2016.
16. WHO. Summary table 7th AugustFINAL.xls - country2003_08_15.pdf. https://www.who.int/csr/sars/country/country2003_08_15.pdf. Published 2003. Accessed.
17. @GlobalHealthBMJ. Sex, gender and COVID-19: Disaggregated data and health disparities | BMJ Global Health blog. 2020.

18. Garg S KL, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020 | MMWR. *MMWR Morb Mortal Wkly Rep*. 2020;69:458–464.
19. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. *N Engl J Med*. 2020;382(16):1564–1567.
20. Johnson HD, Sholcosky D, Gabello K, Ragni R, Ogonosky N. Sex differences in public restroom handwashing behavior associated with visual behavior prompts. *Percept Mot Skills*. 2003;97(3 Pt 1):805–810.
21. Jefferson T, Del Mar CB, Dooley L, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. *Cochrane Database Syst Rev*. 2011(7):Cd006207.
22. Klein SL, Flanagan KL. Sex differences in immune responses. *Nat Rev Immunol*. 2016;16(10):626–638.
23. Jaillon S, Berthenet K, Garlanda C. Sexual Dimorphism in Innate Immunity. *Clin Rev Allergy Immunol*. 2019;56(3):308–321.
24. Berghofer B, Frommer T, Haley G, Fink L, Bein G, Hackstein H. TLR7 ligands induce higher IFN-alpha production in females. *J Immunol*. 2006;177(4):2088–2096.
25. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection. *J Immunol*. 2017;198(10):4046–4053.
26. Jia HP, Look DC, Shi L, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. *J Virol*. 2005;79(23):14614–14621.
27. Gupte M, Thatcher SE, Boustany-Kari CM, et al. Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice. *Arterioscler Thromb Vasc Biol*. 2012;32(6):1392–1399.
28. Zhao Y ZZ, Wang Y, Zhou Y, Ma Y and Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. 2020.
29. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. *Lancet*. 2008;371(9606):64–74.
30. Wu YH, Tseng CP, Cheng ML, Ho HY, Shih SR, Chiu DT. Glucose-6-phosphate dehydrogenase deficiency enhances human coronavirus 229E infection. *J Infect Dis*. 2008;197(6):812–816.
31. Marquez EJ, Chung CH, Marches R, et al. Sexual-dimorphism in human immune system aging. *Nat Commun*. 2020;11(1):751.
32. Giefing-Kroll C, Berger P, Lepperdinger G, Grubeck-Loebenstien B. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. *Aging Cell*. 2015;14(3):309–321.

Table 1	All Patients by Biological Sex									
	Cases	Males				Females				M > F
		Count	%	95% CI		Count	%	95% CI		p-value
Study			Lower (%)	Upper (%)			Lower (%)	Upper (%)	One-Tailed	
SARS, Hong Kong -- Karlberg et al	1755	776	44.22	41.9	46.6	979	55.78	53.5	58.1	1
SARS Toronto--Booth et al	144	56	38.89	31.3	47	88	61.11	53	68.7	0.9962
Total*	144	56	43	19.2	70.6	88	57	29.4	80.8	0.9004
MERS-CoV -- Chen et al	1137	741	65.17	62.4	67.9	396	34.83	32.1	37.6	< 0.0001
MERS-CoV -- Alghamdi et al	422	260	61.61	56.9	66.1	162	38.39	33.9	43.1	< 0.0001
Total*	1559	1001	63.9	40.8	81.9	558	36.1	18.1	59.2	0.0412
COVID19Wuhan University hospital	138	75	54.35	46.03	62.43	63	45.65	37.6	54	0.1535
COVID19 NEJM Guan et al	1096	637	58.12	55.18	61.01	459	41.88	39	44.8	< 0.0001
COVID 19 Wuhan Jinyintan Hospital	99	67	67.68	57.95	76.08	32	32.32	23.9	42.1	0.0002
Total*	1333	779	59.3	45.7	71.6	88	40.7	28.4	54.3	0.04925

* Random Effects Model Results

Table 2	Death Rate by Biological Sex														
	Males					Females					Percent Death		Odds of Death		
	Study	Patients	Deaths	%	95% Wilson CI		Patients	Deaths	%	95% Wilson CI		M > F	M ≠ F	Males to Females	
					Lower (%)	Upper (%)				p-value		Ratio	95% CI		
											One-Tailed	Two-Tailed	Lower	Upper	
MERS-CoV -- Chen et al	741	157	21.2	18.4	24.3	396	60	15.2	12.0	19.0	0.0068	0.0136	1.51	1.086	2.086
MERS-CoV -- Alghamdi et al	260	89	34.2	28.7	40.2	162	31	19.1	13.8	25.9	0.0004	0.0008	2.20	1.378	3.511
SARS, Hong Kong -- Karlberg et al	776	170	21.9	19.1	25.0	979	129	13.2	11.2	15.4	< 0.0001	< 0.0001	1.85	1.438	2.377
Total#	1777	416	25.2	12.1	45.19	1537	220	15	9.6	22.6	< 0.0001	< 0.0001	1.75	1.454	2.247

Mixed Effects Model Results (random intercept with fixed effect for biological sex)

Table 3		COVID19 All Patients by Biological Sex- Incidence							
		Males			Females			M > F	M ≠ F
		95% Score CI			95% CI			p-value	
Country	Cases	%	Lower	Upper	%	Lower	Upper	One-Tailed	Two-Tailed
Italy	57,989	58	57.6	58.4	42	41.6	42.4	< 0.0001	< 0.0001
China	55,924	51	50.6	51.4	49	48.6	49.4	< 0.0001	< 0.0001
Germany	36,508	55	54.5	55.5	45	44.5	45.5	< 0.0001	< 0.0001
Spain	25,113	51	50.4	51.6	49	48.4	49.6	0.0008	0.0015
Iran	14,991	57	56.2	57.8	43	42.2	43.8	< 0.0001	< 0.0001
Switzerland	12,161	49	48.1	49.9	51	50.1	51.9	0.9862	0.0276
South Korea	9,332	39	38.0	40.0	61	60.0	62.0	1.0000	< 0.0001
The Netherlands	8,603	50	48.9	51.1	50	48.9	51.1	0.5000	1.0000
Austria	7,557	53	51.9	54.1	47	45.9	48.1	< 0.0001	< 0.0001
Belgium	7,284	50	48.8	51.2	50	48.8	51.2	0.5000	1.0000
France	6,378	47	45.8	48.2	53	51.8	54.2	1.0000	< 0.0001
Norway	3,581	52	50.4	53.6	48	46.4	49.6	0.0084	0.0169
Sweden	3,046	53	51.2	54.8	47	45.2	48.8	0.0005	0.0010
Portugal	4,268	46	44.5	47.5	54	52.5	55.5	1.0000	< 0.0001
Canada	4,043	52	50.5	53.5	48	46.5	49.6	0.0057	0.0113
Australia	3,010	52	50.2	53.8	48	46.2	49.8	0.0144	0.0287
Denmark	1,715	60	57.7	62.3	40	37.7	42.3	< 0.0001	< 0.0001
Total"	261,503	51.5	48.9	54.0	48.5	46.0	51.1	0.1195	0.2389
" Random Effects Model Results									

Table 4	COVID Death Rate by Biological Sex										Odds of Death			Percent Death	
	Country	Deaths	Death %	Males			Females			Males to Females			M > F	M ≠ F	
				95% Wilson Score CI		Death %	95% Wilson Score CI		Death %	95% Wilson Score CI	Odds Ratio	95% CI		p-value	
				Lower	Upper		Lower	Upper				Lower	Upper	One-Tailed	Two-Tailed
Italy	5,019	8.7	8.43	8.80	10.6	10.27	10.93	6.0	5.69	6.28	1.86	1.75	1.99	<0.0001	<0.0001
China	2,114	3.8	3.63	3.94	4.7	4.50	5.00	2.8	2.59	2.98	1.74	1.59	1.91	<0.0001	<0.0001
Germany	198	0.5	0.47	0.62	0.7	0.55	0.77	0.4	0.32	0.52	1.59	1.19	2.14	0.0009	0.0018
Spain	950	3.8	3.55	4.03	4.8	4.46	5.21	2.7	2.43	3.00	1.82	1.59	2.09	<0.0001	<0.0001
Iran	853	5.7	5.33	6.07	5.9	5.41	6.41	5.4	4.90	6.01	1.09	0.95	1.26	0.1122	0.2244
Switzerland	197	1.6	1.41	1.86	2.0	1.69	2.41	1.2	0.99	1.55	1.64	1.23	2.19	0.0003	0.0007
South Korea	139	1.5	1.26	1.76	2.1	1.65	2.58	1.1	0.88	1.43	1.85	1.32	2.59	0.0001	0.0003
The Netherlands	546	6.3	5.85	6.88	8.1	7.34	8.98	4.4	3.87	5.10	1.90	1.59	2.28	<0.0001	<0.0001
France	161	2.5	2.17	2.94	3.1	2.55	3.80	2.0	1.58	2.53	1.58	1.15	2.16	0.0023	0.0046
Sweden	92	3.0	2.47	3.69	3.4	2.64	4.42	2.6	1.87	3.53	1.34	0.88	2.05	<0.0001	<0.0001
Portugal	76	1.8	1.43	2.22	2.5	1.88	3.26	1.2	0.82	1.72	2.11	1.32	3.39	0.0007	0.0015
Denmark	34	2.0	1.42	2.76	2.4	1.58	3.46	1.4	0.78	2.64	1.65	0.78	3.48	0.0930	0.1860
Total§	10,379	2.3	1.41	3.59	3.4	2.10	5.45	2.1	1.26	3.41	1.84	1.8	1.88	<0.0001	<0.0001
§ Random Effects Model Results															